Skip to navigation Skip to main content Skip to footer

Updates

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in use- Buccolam 10mg

Orifarm UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in one batch of Buccolam 10mg Oromucosal solution has missing information regarding having to break the seal on the inner container before use.

 

MHRA drug alert date: 22nd May 2023

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-orifarm-uk-ltd-buccolam-10mg-oromucosal-solution-el-23-a-slash-18?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=d06c9595-2c98-4c18-90d1-5b738d6dc70d&utm_content=immediately

 

Pip code

Product Description

Affected Batches

ALLIANCE DO NOT STOCK

 

BUCCOLAM 10MG

 

620903600

 

This is a caution in use only we are not accepting stock returns.

 

Further Information

For more information, medical or supply enquiries, please contact 01276 698370, or email uk_enquiries@orifarm.com

 

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in use- Simulect 10mg & 20mg powder and solvent for Solution for injection or infusion

Novartis Pharmaceuticals has informed the MHRA that the solvent (water for injections in ampoules) co-packed with the impacted batches of Simulect powder for injection, may contain glass fragments approximately 20 – 800 µm in size.

 

MHRA drug alert date: 16th May 2023

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-novartis-pharmaceuticals-simulect-10mg-and-20mg-powder-and-solvent-for-solution-for-injection-or-infusion-el-23-a-slash-17?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=d08ff9e2-3185-4fca-b71c-1083f3f9bff0&utm_content=immediately

 

Pip code

Product Description

Affected Batches

2985802

SIMULECT VIAL 10MG

SHVF3

Alliance Healthcare do not stock

 

SIMULECT VIAL 20MG

 

SHWU5

SHEW5

SHFV1

This is a caution in use only we are not accepting stock returns.

 

Further Information

For more information, medical or supply enquiries, please contact 01276 698370, or email medinfo.uk@novartis.com

 

 

 

SUB-TYPE: CLASS 3 RECALL

class 3 recall- Gemcitabine 1g/26.3ml & 2g/52.6ml Solution For Infusion Vial

Hikma Farmacêutica Portugal S.A has informed the MHRA of a potential issue impacting the batches listed in this notification.

 

MHRA Drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-hikma-farmaceutica-portugal-s-dot-a-gemcitabine-1g-slash-26-dot-3ml-and-2g-slash-52-dot-6ml-solution-for-infusion-vial-el-23-a-slash-16

Pip code

Product description

Supplier

Batch Numbers

ALLIANCE DO NOT STOCK

Gemcitabine 1g/26.3ml Solution For Infusion Vial

Hikma Farmacêutica Portugal S.A.

CB0013

ALLIANCE DO NOT STOCK

Gemcitabine 2g/52.6ml Solution For Infusion Vial

Hikma Farmacêutica Portugal S.A.

CB0014

 

For more information or medical information queries, please contact: Portugalcomplaints@hikma.com or Portugaleupharmacovigilance@hikma.com

 

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

SUB-TYPE: CLASS 1 RECALL

Class 1 recall-Emerade 300 & 500 Auto-Injectors

reason: Pharmaswiss Česka republika s.r.o. and distributor Bausch & Lomb UK Limited is recalling all unexpired batches of Emerade 500 micrograms and Emerade 300 micrograms adrenaline auto-injectors (also referred to as pens) from patients. This is due to an issue identified during an ISO 11608 Design Assessment study where some auto-injectors failed to deliver the product or activated prematurely

 

MHRA drug alert date  9th May 2023

 

MHRA ref: MDR 020-05/23

 

Pip code

Product description

Supplier

Batch Numbers

ALLIANCE HEALTHCARE DO NOT STOCK

EMERADE 500 AUTO-INJECTOR

BAUSCH & LOMB

ALL

ALLIANCE HEALTHCARE DO NOT STOCK

EMERADE 300 AUTO-INJECTOR

BAUSCH & LOMB

ALL

 

 

Further Information

For stock enquiries, please contact Bausch & Lomb Customer Services:

Tel: 020 8781 2991

Email: Pharma_CS@bausch.com

 

For medical information enquiries please contact the Medical Information Team:

Email: medinfo.europe@bauschhealth.com

 

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

 

 

SUB-TYPE: COMPANY-LED RECALL

company-led recall: Beambridge 33025 leg bag Short Tube

Beambridge Medical Ltd have informed us that some bags in the affected batch are prone to leaking

 

PIP CODE

DESCRIPTION

SUPPLIER

AFFECTED BATCHES

3739745

BEAMBRIDGE 33025 LEG BAG SHRT SP

Beambridge Medical Ltd

20221030

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

 

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in use- Beconase Hayfever Nasal Spray 180 Dose (P)

Omega Pharma Ltd has identified that there is text missing in Section 2 of the Patient Information Leaflet (PIL) in packs of Beconase Hayfever Nasal Spray (P).

 

MHRA drug alert date: 26th April 2023

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-omega-pharma-ltd-beconase-hayfever-nasal-spray-el-23-a-slash-15?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=bcaed696-a02b-4ec1-bbed-8bd2b462dab8&utm_content=immediately

 

Pip code

Product Description

Affected Batches

2149839

 

BECONASE ALLERGY 180 SPRAYS

SEE LINK ABOVE

This is a caution in use only we are not accepting stock returns.

 

Further Information

For medical information, stock control queries and Patient Information Leaflet (PIL) requests, please contact: UKLOcustomerservice@perrigo.com

 

 

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in use- Co-amoxiclav 125/31.25mg/5ml, 250/62.5mg/5ml powder for oral suspension

Sandoz limited has informed the MHRA that the products mentioned in this notification are not sugar free despite the carton stating ‘sugar free’. The ‘sugar free’ text was added to the carton in December 2008 in error.

MHRA drug alert date: 20th April 2023

 

MHRA drug alert link:  https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-sandoz-limited-co-amoxiclav-125-slash-31-dot-25mg-slash-5ml-250-slash-62-dot-5mg-slash-5ml-powder-for-oral-suspension-el-23-a-slash-14?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=8bedc9fd-dd67-44c7-8691-89546eb2ed97&utm_content=immediately#contents

Pip code

Product Description

Livery

Affected Batches

1117290

 

CO-AMOXICLAV 125/31.25MG ALM

 

ALMUS

LL9525 LM7892 MB7218

 

1117308

 

CO-AMOXICLAV 250/62.5MG ALM

 

ALMUS

LM6707 LM7608 MB7828 MG9435

 

1117290

CO-AMOXICLAV 125/31.25MG

SANDOZ

SEE LINK ABOVE

1117308

CO-AMOXICLAV 250/62.5MG

SANDOZ

SEE LINK ABOVE

 

 

This is a caution in use only we are not accepting stock returns.

 

Further Information

For more information, medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101

 

For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Caution in use- Briviact 75mg & 100mg film coated tablets

Ethigen Limited have informed the MHRA that the Patient Information Leaflet (PIL) in Briviact 75mg and Briviact 100mg film coated tablets contains incorrect or missing information.

 

MHRA drug alert date: 30th March 2023

 

MHRA drug alert link:  https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-ethigen-limited-briviact-75mg-and-100mg-film-coated-tablets-el-23-a-slash-13?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=029a9973-e8e8-4dc1-99ae-a45b0b7f8b12&utm_content=immediately

 

 

Pip code

Product Description

Affected Batches

ALLIANCE HEALTHCARE DO NOT STOCK

BRIVIACT FILM COATED TABS 75MG

340132       332075

ALLIANCE HEALTHCARE DO NOT STOCK

BRIVIACT FILM COATED TABS 100MG

332076

329941

337225

332072

329491

337216

339975

337216

343194

349497

343190

349527

 

 

This is a caution in use only we are not accepting stock returns.

 

Further Information

For medical information and stock control queries please contact the Regulatory Affairs Department at regulatory@ethigen.co.uk.

 

SUB-TYPE: CLASS 2 RECALL

Class 2 recall-GONAPEPTYL Depot 3.75mg

Reason: “Ferring Pharmaceuticals Limited is recalling certain batches of GONAPEPTYL Depot 3.75mg due to a defect noticed in the seal of the needle wrapping for the CE-marked 30-millimeter (30mm) needle for subcutaneous injection that is supplied with each product pack.”

 

MHRA drug alert date  23rd March 2023

 

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ferring-pharmaceuticals-limited-gonapeptyl-depot-3-dot-75mg-powder-and-solvent-for-suspension-for-injection-el-23-a-slash-12

 

  • MHRA ref: MDR 065-03/23

 

Pip code

Product description

Supplier

Batch Numbers

ALLIANCE HEALTHCARE DO NOT STOCK

GONAPEPTYL DEPOT PFS 3.75MG    

FERRING PHARMACEUTICALS

T16656K
U11271E
U11271F
U11386G
U11570E
U11571E
U15102C
U15102K
U15102L

 

Further Information

For all medical enquiries, please contact medical information: medical.uk@ferring.com.

For supply queries, please contact customer services: customer.services@ferring.com

 

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

 

SUB-TYPE: CLASS 3 RECALL

Class 3 Recall - Sildenafil 10mg/ml Oral Suspension

CLASS 3 RECALL -  SILDENAFIL 10MG/ML ORAL SUSPENSION

 

Rosemont Pharmaceuticals Limited has informed the MHRA that the Press In Bottle Adaptor (PIBA) supplied with the pack (carton) in the batch listed above is too wide to fit the neck of the medicine.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-rosemont-pharmaceuticals-limited-sildenafil-10mg-slash-ml-oral-suspension-el-23-a-slash-11?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=7d86bb08-f180-4501-855c-2a3380963267&utm_content=immediately

Pip code

Product description

Supplier

Batch numbers

8045130

Sildenafil 10mg/ml Oral Suspension

Rosemont Pharmaceuticals Limited

SLD22002

 

For more information, medical information queries or replacement PIBA enquiries, please contact: pharmacovigilance@rosemontpharma.com.

 

For stock control queries, please contact: customerservices@rosemontpharma.com.

 

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.